Iron, atherosclerosis, and neurodegeneration: A key role for cholesterol in promoting iron-dependent oxidative damage?

Annals of the New York Academy of Sciences

Volumn 1012, Issue , 2004, Pages 51-64

  Ong, Wei Yi ^a   Halliwell, Barry ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Alzheimer's disease; Atherosclerosis; Brain; Cholesterol; Hypercholesterolemia; Iron; Statin; Transferrin

Indexed keywords

4 [2 [1 (4 CHLOROCINNAMYL) 4 PIPERAZINYL]ETHYL]BENZOIC ACID; AMYLOID BETA PROTEIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; MEVINOLIN; PRAVASTATIN; STATINE DERIVATIVE;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD BRAIN BARRIER; BRAIN; CATALYSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; HUMAN; HYPERCHOLESTEROLEMIA; IRON STORAGE; IRON TRANSPORT; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN AGGREGATION; REVIEW; RISK FACTOR;

EID: 1842608817     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1306.005     Document Type: Review

References (110)

1. CHEN, Q., J.L. BEARD & B.C. JONES. 1995. Abnormal rat brain monoamine metabolism in iron deficiency anemia. J. Nutr. Biochem. 5: 486-493.
2. CONNOR, J.R., S.L. MENZIES, J.R. BURDO & P.J. BOYER. 2001. Iron and iron management proteins in neurobiology. Pediatr. Neurol. 25: 118-129.
3. CONNOR, J.R., B.S. SNYDER, J.L. BEARD et al. 1992. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J. Neurosci. Res. 31: 327-335.
4. MORRIS, C.M., J.M. CANDY, A.E. OAKLEY et al. 1992. Histochemical distribution of non-haem iron in the human brain. Acta Anat. 144: 235-257.
5. WAGNER, K.R., F.R. SHARP, T.D. ARDIZZONE et al. 2003. Heme and iron metabolism: role in cerebral hemorrhage. J. Cereb. Blood Flow Metab. 23: 629-652.
6. WILLMORE, L.J. 1990. Post-traumatic epilepsy: cellular mechanisms and implications for treatment. Epilepsia 31: S67-S73.
7. ONG, W.Y., B.K.C. ONG, A.A. FAROOQUI et al. 2003. Iron and epilepsy. In Metal Ions and Neurodegenerative Disorders, pp. 365-398. World Scientific. Singapore.
8. MOOS, T. & E.H. MORGAN. 2000. Transferrin and transferrin receptor function in brain barrier systems. Cell. Mol. Neurobiol. 20: 77-95.
9. WANG, X.S., W.Y. ONG & J.R. CONNOR. 2001. A light and electron microscopic study of the iron transporter protein DMT-1 in the monkey cerebral neocortex and hippocampus. J. Neurocytol. 30: 353-360.
10. WANG, X.S., W.Y. ONG & J.R. CONNOR. 2002. A light and electron microscopic study of divalent metal transporter-1 distribution in the rat hippocampus, after kainate-induced neuronal injury. Exp. Neurol. 177: 193-201.
11. JEONG, S.Y. & S. DAVID. 2003. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J. Biol. Chem. 278: 27144-27148.
12. GANONG, W.F. 2001. Review of Medical Physiology. Twentieth edition. McGraw-Hill. New York.
13. DIETSCHY, J.M. & S.D. TURLEY. 2001. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12: 105-112.
14. VEGA, G.L., M.F. WEINER, A.M. LIPTON et al. 2003. Reduction in levels of 245-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch. Neurol. 60: 510-515.
15. ONG, W.Y., E.W.S. GOH, X.R. LU et al. 2003. Increase in cholesterol and cholesterol oxidation products, and role of cholesterol oxidation products in kainate-induced neuronal injury. Brain Pathol. 13: 250-262.
16. BLANN, A.D., T. NAQVI, M. WAITE & C.N. MCCOLLUM. 1993. Von Willebrand factor and endothelial damage in essential hypertension. J. Hum. Hypertens. 7: 107-111.
17. BELGORE, F.M., A.D. BLANN, F.L. LI-SAW-HEE et al. 2001. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am. J. Cardiol. 87: 805-807.
18. FELMEDEN, D.C., C.G. SPENCER, F.M. BELGORE et al. 2003. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am. J. Hypertens. 16: 11-20.
19. CHISOLM, G.M. & D. STEINBERG. 2000. The oxidative modification hypothesis of atherogenesis: an overview. Free Radical Biol. Med. 28: 1815-1826.
20. SMITH, C., M.J. MITCHINSON, O.I. ARUOMA & B. HALLIWELL. 1992. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem. J. 286: 901-905.
21. SATOH, T. & O. TOKUNAGA. 2002. Intracellular oxidative modification of low density lipoprotein by endothelial cells. Virchows Arch. 440: 410-417.
22. STEINBERG, D., S. PARTHASARATHY, T.E. CAREW et al. 1989. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320: 915-924.
23. GOLDSTEIN, J.L. & M.S. BROWN. 1977. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu. Rev. Biochem. 46: 897-930.
24. CHAIT, A. & J.W. HEINECKE. 1994. Lipoprotein modification: cellular mechanisms. Curr. Opin. Lipidol. 5: 365-370.
25. HALLIWELL, B. 2003. Oxidative stress in cell culture: an under-appreciated problem? FEBS Lett. 540: 3-6.
26. CRANE, F.L., I.L. SUN, M.G. CLARK et al. 1985. Transplasma-membrane redox systems in growth and development. Biochim. Biophys. Acta 811: 233-264.
27. GARNER, B., D. VAN REYK, R.T. DEAN & W. JESSUP. 1997. Direct copper reduction by macrophages: its role in low density lipoprotein oxidation. J. Biol. Chem. 272: 6927-6935.
28. WITZ, G. 1989. Biological interaction of α,β-unsaturated aldehydes. Free Radical Biol. Med. 7: 333-349.
29. TERAO, J. 1990. Reactions of lipid hydroperoxides. In Membrane Lipid Oxidation, pp. 219-238. CRC Press. Boca Raton, FL.
30. GIROTTI, A.W. 1998. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J. Lipid Res. 39: 1529-1542.
31. ITABE, H. 1998. Oxidized phospholipids as a new landmark in atherosclerosis. Prog. Lipid Res. 37: 181-207.
32. KARTEN, B., H. BOECHZELT, P.M. ABUJA et al. 1999. Macrophage-enhanced formation of cholesteryl ester-core aldehydes during oxidation of low density lipoprotein. J. Lipid Res. 40: 1240-1253.
33. SMITH, L.L. 1981. Cholesterol Autoxidation. Plenum. New York
34. SMITH, L.L. & B.H. JOHNSON. 1989. Biological activites of oxysterols. Free Radical Biol. Med. 7: 285-332.
35. LIZARD, G., S. GUELDRY, O. SORDET et al. 1998. Glutathione is implied in the control of 7-ketocholesterol-induced apoptosis, which is associated with radical oxygen species production. FASEB J. 12: 1651-1663.
36. CLARE, K., S.J. HARDWICK, K.L.H. CARPENTER et al. 1995. Toxicity of oxysterols to human monocytes-macrophages. Atherosclerosis 118: 67-75.
37. LEONARDUZZI G., B. SOTTERO & G. POLI. 2002. Oxidized products of cholesterol: dietary and metabolic origin, and proatherosclerotic effects (review). J. Nutr. Biochem. 13: 700-710.
38. FERRARI, M., G.S. WERNER, J. RIEBER et al. 2001. No influence of hemochromatosis-related gene mutations on restenosis rate in a retrospective study of 137 patients after coronary stent implantation. Int. J. Cardiovasc. Intervent. 4: 181-186.
39. THONG, P.S., M. SELLEY & F. WATT. 1996. Elemental changes in atherosclerotic lesions using nuclear microscopy. Cell. Mol. Biol. 42: 103-110.
40. PONRAJ, D., J. MAKJANIC, P.S. THONG et al. 1999. The onset of atherosclerotic lesion formation in hypercholesterolemic rabbit is delayed by iron depletion. FEBS Lett. 459: 218-222.
41. SCHMITZ, S.A., S.E. COUPLAND, R. GUST et al. 2000. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest. Radiol. 35: 460-471.
42. SCHMITZ, S.A., M. TAUPITZ, S. WAGNER et al. 2001. Magnetic resonance imaging of atherosclerotic plaques using Superparamagnetic iron oxide particles. J. Magn. Reson. Imaging 14: 355-361.
43. DABBAGH, A.J., G.T. SHWAERY, J.F. KEANEY, JR. & B. FREI. 1997. Effect of iron overload and iron deficiency on atherosclerosis in the hypercholesterolemic rabbit. Arterioscler. Thromb. Vasc. Biol. 17: 2638-2645.
44. REN, M., F. WATT, B.H. TAN & B. HALLIWELL. 2003. Correlation of iron and zinc levels with lesion depth in newly formed atherosclerotic lesions. Free Radical Biol. Med. 34: 746-752.
45. HALLIWELL, B. & J.M. GUTTERIDGE. 1990. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 186: 1-85.
46. ZHANG, H.F., W.Y. ONG & S.K. LEONG. 1997. Ultrastructural changes in cerebral cortical blood vessels of immature and adult rats after a single episode of neonatal hypoxia. J. Hirnforsch. 38: 81-97.
47. ZHANG, H.F., W.Y. ONG, S.K. LEONG & L.J. GAREY. 1997. Ultrastructural characteristics of blood vessels in the infant and adult human cerebral cortex. Histol. Histopathol. 12: 85-97.
48. AYDEMIR, E.O., C. DUMAN, H.A. CELIK et al. 2000. Effects of defibrotide on aorta and brain malondialdehyde and antioxidants in cholesterol-induced atherosclerotic rabbits. Int. J. Clin. Lab. Res. 30: 101-107.
49. DE LA CRUZ, J.P., L. QUINTERO, M.A. VILLALOBOS & F. SANCHEZ DE LA CUESTA. 2000. Lipid peroxidation and glutathione system in hyperlipidemic rabbits: influence of olive iol administration. Biochim. Biophys. Acta 1485: 36-44.
50. GOKKUSU, C. & T. MOSTAFAZADEH. 2003. Changes of oxidative stress in various tissues by long-term administration of vitamin E in hypercholesterolemic rats. Clin. Chim. Acta 328: 155-161.
51. PRACTICO, D., J. ROKACH & R.K. TANGIRALA. 1999. Brains of aged apolipoprotein E-deficient mice have increased levels of F2-isoprostanes, in vivo markers of lipid peroxidation. J. Neurochem. 73: 736-741.
52. MORROW, J.D., B. FREI, A.W. LONGMIRE et al. 1995. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. N. Engl. J. Med. 332: 1198-1203.
53. PRACTICO, D., R. TANGIRALA, D. RADAR et al. 1998. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apoE-deficient mice. Nat. Med. 4: 1189-1192.
54. DUPUY, A.M., E. MAS, K. RITCHIE et al. 2001. The relationship between apolipoprotein E4 and lipid metabolism is impaired in Alzheimer's disease. Gerontology 47: 213-218.
55. ONG, W.Y., M.Q. REN, J. MAKJANIC et al. 1999. A nuclear microscopic study of elemental changes in the rat hippocampus after kainate-induced neuronal injury. J. Neurochem. 72: 1574-1579.
56. WANG, X.S., W.Y. ONG & J.R. CONNOR. 2002. Increase in ferric and ferrous iron in the rat hippocampus with time after kainate-induced excitotoxic injury. Exp. Brain Res. 143: 137-148.
57. ONG, W.Y., B. TAN, N. PAN et al. 2004. Increased iron staining in the cerebral cortex of cholesterol fed rabbits. Mech. Ageing Dev. In press.
58. VAN DEURS, B., O.W. PETERSEN, S. OLSNES & K. SANDVIG. 1989. The ways of endocytosis. Int. Rev. Cytol. 117: 131-177.
59. SANDVIG, K. & B. VAN DEURS. 1994. Endocytosis without clathrin. Trends Cell Biol. 4: 275-277.
60. SANDVIG, K. & B. VAN DEURS. 1996. Endocytosis, intracellular transport, and cytotoxic action of shiga toxin and ricin. Am. Physiol. Soc. 76: 949-965.
61. SCHMID, S.L. 1997. Clathrin-coated vesicle formation and protein sorting: an integrated process. Annu. Rev. Biochem. 6: 511-548.
62. DAMKE, H., T. BABA, D.E. WARNOCK & S.L. SCHMID. 1994. Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J. Cell Biol. 127: 915-934.
63. DAMKE, H., T. BABA, A.M. VAN DER BLIEK & S.L. SCHMID. 1995. Clathrin-independent pinocytosis is induced in cells overexpressing a temperature-sensitive mutant of dynamin. J. Cell Biol. 131: 69-80.
64. OH, P., D.P. MCINTOSH & J.E. SCHNITZER. 1998. Dynamin at the neck of caveolae mediates their budding to form transport vesicles by GTP-driven fission from the plasma membrane of endothelium. J. Cell Biol. 141: 101-114.
65. HENLEY, J.R., E.W. KRUEGER, B.J. OSWALD & M.A. MCNIVEN. 1998. Dynamin-mediated internalization of caveolae. J. Cell Biol. 141: 85-99.
66. VIRGINTINO, D., D, ROBERTSON, M. ERREDE et al. 2002. Expression of caveolin-1 in human brain microvessels. Neuroscience 115: 145-152.
67. FIELDING, C.J., A. BIST & P.E. FIELDING. 1997. Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers. Proc. Natl. Acad. Sci. USA 94: 3753-3758.
68. BIST, A., P.E. FIELDING & C.J. FIELDING. 1997. Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol, Proc. Natl. Acad. Sci. USA 94: 10693-10698.
69. BROUET, A., P. SONVEAUX, C. DESSY et al. 2001. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ. Res. 89: 866-873.
70. DRAB, M., P. VERKADE, M. ELGER et al. 2001. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293: 2449-2452.
71. SIMIONESCU, M., A. GAFENCU & F. ANTOHE. 2002. Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey. Microsc. Res. Tech. 57: 269-288.
72. DAUTRY-VARSAT, A. 1986. Receptor-mediated endocytosis: the intracellular journey of transferrin and its receptor. Biochimie 68: 375-381.
73. RODAL, S.K., G. SKRETTING, O. GARRED et al. 1999. Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol. Biol. Cell 10: 961-974.
74. ADAMS, R., M. VICTOR & A.H. ROPPER. 1997. Principles of Neurology. Sixth edition. McGraw-Hill. New York.
75. NUBIOLA, A.R., L. MASANA, S. MASDEU & J. RUBIES-PRAT. 1981. High-density lipoprotein cholesterol in cerebrovascular disease. Arch. Neurol. 38: 468.
76. WHITE, H.D., R.J. SIMES, N.E. ANDERSON et al. 2000. Pravastatin therapy and the risk of stroke. N. Engl. J. Med. 343: 317-326.
77. BLAUW, G.J., A.M. LAGAAY, A.H. SMELT & R.G. WESTENDORP. 1997. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 28: 946-950.
78. CROUSE, J.R., III, R.P. BYINGTON, H.M. HOEN & C.D. FURBERG. 1997. Reductase inhibitor monotherapy and stroke prevention. Arch. Intern. Med. 157: 1305-1310.
79. SCHWARTZ, G.G., A.G. OLSSON, M.D. EZEKOWITZ et al. 2001. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes - the MIRACL study: a randomized controlled trial. JAMA 285: 1711-1718.
80. WATERS, D.D., G.G. SCHWARTZ, A.G. OLSSON et al. 2002. Effects of atorvastatin on stroke in patients with unstable angina on non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 106: 1690-1695.
81. COLLINS, R., J. ARMITAGE, S. PARISH et al. 2003. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-2016.
82. DELANTY, N. & C.J. VAUGHAN. 1997. Vascular effects of statins in stroke. Stroke 28: 2315-2320.
83. AMARENCO, P., A. COHEN, C. TZOURIO et al. 1994. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N. Engl. J. Med. 331: 1474-1479.
84. DRESSLER, F.A., W.R. CRAIG, R. CASTELLO & A.J. LABOVITZ. 1998. Mobile aortic atheroma and systemic emboli: efficacy of anticoagulation and influence of plaque morphology on recurrent stroke. J. Am. Coll. Cardiol. 31: 134-138.
85. AMIN-HANJANI, S., N.E. STAGLIANO, M. YAMADA et al. 2001. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32: 980-986.
86. CHEN, J., Z.G. ZHANG, Y. LI et al. 2003. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann. Neurol. 53: 743-751.
87. VAUGHAN, C.J. 2003. Prevention of stroke and dementia with statins: effects beyond lipid lowering. Am. J. Cardiol. 91: 23B-29B.
88. BALDUINI, W., E. MAZZONI, S. CARLONI et al. 2003. Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin-1β and tumor necrosis factor-α mRNA induction, and does not affect endothelial nitric oxide synthase expression. Stroke 34: 2007-2012.
89. ERKINJUNTTI, T. & K. ROCKWOOD. 2003. Vascular dementia. Semin. Clin. Neuropsychiatry 8: 37-45.
90. STERZER, P., F. MEINTZSCHEL, A. ROSLER et al. 2001. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke 32: 2817-2820.
91. BUTTERFIELD, D.A. 2002. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain - a review. Free Radical Res. 36: 1307-1313.
92. DRAKE, J., C.D. LINK & D.A. BUTTERFIELD. 2003. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol. Aging 24: 415-420.
93. CORDER, E.H., A.M. SAUNDERS, W.J. STRITTMATTER et al. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.
94. HOFMAN, A., A. OTT, M.M. BRETELER et al. 1997. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349: 151-154.
95. BALES, K.R., T. VERINA, R.C. DODEL et al. 1997. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17: 263-264.
96. PAPASSOTIROPOULOS, A., D. LUTJOHANN, M. BAGLI et al. 2002. 24S-Hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 36: 27-32.
97. BUSH, A.I. 2003. The metallobiology of Alzheimer's disease. Trends Neurosci. 26: 207-214.
98. JARVIK, G.P., E.M. WIJSMAN, W.A. KUKULL et al. 1995. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45: 1092-1096.
99. NOTKOLA, I.L., R. SULKAVA, J. PEKKANEN et al. 1998. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17: 14-20.
100. PAPPOLLA, M.A., T.K. BRYANT-THOMAS, D. HERBERT et al. 2003. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61: 199-205.
101. JICK, H., G.L. ZORNBERG, S.S. JICK et al. 2000. Statins and the risk of dementia. Lancet 356: 1627-1631.
102. WOLOZIN, B., W. KELLMAN, P. RUOSSEAU et al. 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57: 1439-1443.
103. SPARKS, D.L., S.W. SCHEFF, J.C. HUNSAKER III et al. 1994. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126: 88-94.
104. BODOVITZ, S. & W.L. KLEIN. 1996. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 271: 4436-4440.
105. HOWLAND, D.S., S.P. TRUSKO, M.J. SAVAGE et al. 1998. Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J. Biol. Chem. 273: 16576-16582.
106. SIMONS, M., P. KELLER, B. DE STROOPER et al. 1998. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 95: 6460-6464.
107. REFOLO, L.M., B. MALESTER, J. LAFRANCOIS et al. 2000. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7: 321-331.
108. FASSBENDER, K., M, SIMONS, C. BERGMANN et al. 2001. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides A beta 42 and A beta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98: 5856-5861.
109. PENTACESKA, S.S., S. DEROSA, V. OLM et al. 2002. Statin therapy for Alzheimer's disease: will it work? J. Mol. Neurosci. 19: 155-161.
110. REFOLO, L.M., M.A. PAPPOLLA, J. LAFRANCOIS et al. 2001. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8: 890-899.